Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

Summary

The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.

Timeline

Start

2006-02

Primary completion

2007-11

Completion

2008-08

Outcome

Met primary endpoint

paper The continuous abstinence rate was higher for varenicline than placebo during weeks 9 through 12 (47.0% versus 13.9% PMID 20048210 ↗

registry Varenicline (Var) vs Placebo (Pbo); p <0.0001; Odds Ratio (OR) 6.05 (95% CI 4.13 to 8.86) NCT00282984 ↗

Publications

• Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.
• Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010 Jan 19;121(2):221-9. doi: 10.1161/CIRCULATIONAHA.109.869008. Epub 2010 Jan 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varenicline	Small molecule	1 mg	Oral

Indications

No indication recorded.